HC Wainwright Weighs in on Rockwell Medical, Inc.’s Q4 2024 Earnings (NASDAQ:RMTI)

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities research analysts at HC Wainwright dropped their Q4 2024 EPS estimates for shares of Rockwell Medical in a report issued on Monday, March 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.01. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Rockwell Medical’s FY2025 earnings at $0.06 EPS.

Rockwell Medical Price Performance

RMTI stock opened at $1.64 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.73 and a quick ratio of 1.38. Rockwell Medical has a one year low of $1.16 and a one year high of $6.24. The stock has a market cap of $48.10 million, a PE ratio of -4.10 and a beta of 1.16. The firm has a 50 day simple moving average of $1.41 and a two-hundred day simple moving average of $1.71.

Hedge Funds Weigh In On Rockwell Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Armistice Capital LLC lifted its holdings in shares of Rockwell Medical by 631.7% in the 3rd quarter. Armistice Capital LLC now owns 2,817,000 shares of the company’s stock worth $5,859,000 after acquiring an additional 2,432,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in Rockwell Medical by 185.3% during the 4th quarter. Vanguard Group Inc. now owns 1,074,975 shares of the company’s stock valued at $2,032,000 after buying an additional 698,160 shares during the last quarter. Perkins Capital Management Inc. raised its holdings in Rockwell Medical by 366.3% during the 4th quarter. Perkins Capital Management Inc. now owns 349,934 shares of the company’s stock valued at $661,000 after buying an additional 274,891 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Rockwell Medical by 343.5% during the 2nd quarter. Renaissance Technologies LLC now owns 349,115 shares of the company’s stock valued at $1,906,000 after buying an additional 270,400 shares during the last quarter. Finally, Raymond James & Associates raised its holdings in Rockwell Medical by 15.9% during the 4th quarter. Raymond James & Associates now owns 220,979 shares of the company’s stock valued at $418,000 after buying an additional 30,309 shares during the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.